Oncology Companion Diagnostics Global Market Report 2025

Description

Oncology companion diagnostics are medical tests designed to identify specific biomarkers, indicating which patients are most likely to respond favorably to a particular cancer treatment. These diagnostics play a crucial role in the development and application of targeted therapies, ensuring that treatments are customized to match the unique characteristics of a patient's tumor. By providing insights into the molecular and genetic profile of cancer, companion diagnostics enable more personalized and efficient treatment strategies, leading to improved outcomes and reduced adverse effects.

The primary products within the oncology companion diagnostics market include instruments, consumables, and software. Instruments encompass a diverse array of tools and devices utilized for various purposes across different fields. These diagnostics cater to a range of disease types such as melanoma, breast cancer, colorectal cancer, leukemia, prostate cancer, among others. They leverage various technologies including immunohistochemistry (IHC), in situ hybridization (ISH) or fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), next-generation sequencing (NGS), and others. End users of oncology companion diagnostics include hospitals, pathology or diagnostic laboratories, academic medical centers, and others.

The oncology companion diagnostics market research report is one of a series of new reports from The Business Research Company that provides oncology companion diagnostics market statistics, including oncology companion diagnostics industry global market size, regional shares, competitors with an oncology companion diagnostics market share, detailed oncology companion diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the oncology companion diagnostics industry. This oncology companion diagnostics research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oncology companion diagnostics market size has grown rapidly in recent years. It will grow from $3.35 billion in 2024 to $3.8 billion in 2025 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to increasing cases of adverse drug reactions, increasing demand for comprehensive genomic testing, the increasing global incidence of cancer, the growing need for targeted therapy, and the growing number of clinical trials.

The oncology companion diagnostics market size is expected to see rapid growth in the next few years. It will grow to $6.21 billion in 2029 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period can be attributed to the rising importance of personalized medicine, increasing diagnostic tests, increasing focus on personalized cancer therapy, increasing healthcare expenditure, and increasing cancer incidence and awareness. Major trends in the forecast period include advancements in diagnostic technologies, next-generation sequencing (NGS), integration of artificial intelligence (AI), liquid biopsy technologies, the development of point-of-care companion diagnostic devices, and innovative testing technologies.

The increasing prevalence of cancer is expected to drive the growth of the oncology companion diagnostics market in the future. Cancer is a complex group of diseases characterized by abnormal cell growth that spreads uncontrollably. The rise in cancer cases can be attributed to factors such as lifestyle changes, environmental influences, the obesity epidemic, tobacco use, and genetic predispositions. Oncology companion diagnostics play a critical role in precision medicine, transforming cancer care by enabling personalized treatment selection, improving treatment effectiveness, reducing side effects, facilitating clinical trial participation, and enhancing treatment monitoring. For example, the National Cancer Institute, a US-based government agency, reported in May 2024 that approximately 20 million new cancer cases and 9.7 million cancer-related deaths occurred annually in 2022. By 2040, predictions suggest that the number of new cancer cases will rise to 29.9 million, with 15.3 million cancer-related deaths annually. As a result, the increasing cancer incidence is driving the growth of the oncology companion diagnostics market.

Leading companies in the oncology companion diagnostics market are concentrating their efforts on developing innovative products, particularly in vitro diagnostic tests, to maintain their competitive edge. In vitro diagnostic tests, conducted on samples obtained from patients outside of the body in controlled laboratory environments, provide critical insights into tumor biology and guide treatment decision-making. For example, Illumina Inc., a prominent biotechnology company, introduced a pan-cancer companion diagnostic (CDx) indication for its TruSight Oncology (TSO) Comprehensive (EU) test in May 2022. This diagnostic assay offers a comprehensive tumor profile by evaluating multiple tumor genes and biomarkers, empowering healthcare providers to tailor targeted therapy for patients with various solid malignant neoplasms. By assessing essential parameters such as tumor mutational burden (TMB) and microsatellite instability (MSI) status, this test enhances treatment precision and effectiveness.

In January 2024, Agilent Technologies Inc., a US-based diagnostics company, entered into a partnership with Incyte Corporation for an undisclosed amount. This collaboration aims to strengthen Agilent's companion diagnostics portfolio and support Incyte's hematology and oncology treatments through advanced, precision diagnostics. Incyte Corporation, a US-based pharmaceutical company, specializes in the development and commercialization of oncology medications.

Major companies operating in the oncology companion diagnostics market are F. Hoffmann-La Roche AG, Bayer Diagnostic, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., bioMerieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corporation, BGI Genomics Co. Ltd., Natera Inc., Myriad Genetics Inc., ARUP Laboratories, NeoGenomics Laboratories Inc., Guardant Health, Ambry Genetics Corporation, Biocartis SA, CENTOGENE N.V., Invivoscribe Inc., Pillar Biosciences Inc.

North America was the largest region in the oncology companion diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncology companion diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oncology companion diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oncology companion diagnostics market consists of revenues earned by entities by providing services such as biomarker testing, patient stratification, monitoring treatment response, predicting drug resistance, clinical trial enrollment, comprehensive genomic testing, therapy resistance testing, hereditary cancer testing, and risk assessment. The market value includes the value of related goods sold by the service provider or included within the service offering. The oncology companion diagnostics market also includes sales of polymerase chain reaction instruments, immunohistochemistry (IHC) staining kits, companion diagnostic test kits, liquid biopsy platforms, gene expression profiling kits, mass spectrometry systems, flow cytometry analyzers, tissue microarray instruments, and electrochemical biosensors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oncology Companion Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oncology companion diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oncology companion diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oncology companion diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Product: Instrument; Consumables; Software
2) By Disease Type: Melanoma; Breast Cancer; Colorectal Cancer; Leukemia; Prostate Cancer; Other Disease Types
3) By Technology: Immunohistochemistry (IHC); In Situ Hybridization (ISH) Or Fluorescence In Situ Hybridization (FISH); Polymerase Chain Reaction (PCR); Next-Generation Sequencing (NGS); Other Technologies
4) By End User: Hospital; Pathology Or Diagnostic Laboratory; Academic Medical Center; Other End-Users
Subsegments:
1) By Instrument: Polymerase Chain Reaction (Pcr) Instruments; Next-Generation Sequencing (Ngs) Systems; Immunohistochemistry (Ihc) Instruments; Fluorescence In Situ Hybridization (Fish) Instruments; Microarray Platforms
2) By Consumables: Reagents And Kits (Dna Or Rna Extraction Kits, Pcr Reagents); Biopsy Needles; Testing Slides And Chips; Control And Calibration Samples
3) By Software: Data Analysis Software; Bioinformatics Software ( For Gene Expression Analysis); Companion Diagnostic Decision Support Software; Clinical Workflow Management Software
Companies Mentioned: F. Hoffmann-La Roche AG; Bayer Diagnostic; Thermo Fisher Scientific Inc.; Abbott Laboratories; Danaher Corporation
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r30813

1. Executive Summary

2. Oncology Companion Diagnostics Market Characteristics

3. Oncology Companion Diagnostics Market Trends And Strategies

4. Oncology Companion Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Oncology Companion Diagnostics Growth Analysis And Strategic Analysis Framework

5.1. Global Oncology Companion Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Oncology Companion Diagnostics Market Growth Rate Analysis
5.4. Global Oncology Companion Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Oncology Companion Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Oncology Companion Diagnostics Total Addressable Market (TAM)

6. Oncology Companion Diagnostics Market Segmentation

6.1. Global Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Instrument
Consumables
Software
6.2. Global Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Melanoma
Breast Cancer
Colorectal Cancer
Leukemia
Prostate Cancer
Other Disease Types
6.3. Global Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immunohistochemistry (IHC)
In Situ Hybridization (ISH) Or Fluorescence In Situ Hybridization (FISH)
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Other Technologies
6.4. Global Oncology Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital
Pathology Or Diagnostic Laboratory
Academic Medical Center
Other End-Users
6.5. Global Oncology Companion Diagnostics Market, Sub-Segmentation Of Instrument, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Polymerase Chain Reaction (PCR) Instruments
Next-Generation Sequencing (NGS) Systems
Immunohistochemistry (IHC) Instruments
Fluorescence In Situ Hybridization (FISH) Instruments
Microarray Platforms
6.6. Global Oncology Companion Diagnostics Market, Sub-Segmentation Of Consumables, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Reagents And Kits (DNA Or RNA Extraction Kits, PCR Reagents)
Biopsy Needles
Testing Slides And Chips
Control And Calibration Samples
6.7. Global Oncology Companion Diagnostics Market, Sub-Segmentation Of Software, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Data Analysis Software
Bioinformatics Software (For Gene Expression Analysis)
Companion Diagnostic Decision Support Software
Clinical Workflow Management Software

7. Oncology Companion Diagnostics Market Regional And Country Analysis

7.1. Global Oncology Companion Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Oncology Companion Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oncology Companion Diagnostics Market

8.1. Asia-Pacific Oncology Companion Diagnostics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oncology Companion Diagnostics Market

9.1. China Oncology Companion Diagnostics Market Overview
9.2. China Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oncology Companion Diagnostics Market

10.1. India Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oncology Companion Diagnostics Market

11.1. Japan Oncology Companion Diagnostics Market Overview
11.2. Japan Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oncology Companion Diagnostics Market

12.1. Australia Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oncology Companion Diagnostics Market

13.1. Indonesia Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oncology Companion Diagnostics Market

14.1. South Korea Oncology Companion Diagnostics Market Overview
14.2. South Korea Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oncology Companion Diagnostics Market

15.1. Western Europe Oncology Companion Diagnostics Market Overview
15.2. Western Europe Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oncology Companion Diagnostics Market

16.1. UK Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oncology Companion Diagnostics Market

17.1. Germany Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oncology Companion Diagnostics Market

18.1. France Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oncology Companion Diagnostics Market

19.1. Italy Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oncology Companion Diagnostics Market

20.1. Spain Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oncology Companion Diagnostics Market

21.1. Eastern Europe Oncology Companion Diagnostics Market Overview
21.2. Eastern Europe Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oncology Companion Diagnostics Market

22.1. Russia Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oncology Companion Diagnostics Market

23.1. North America Oncology Companion Diagnostics Market Overview
23.2. North America Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oncology Companion Diagnostics Market

24.1. USA Oncology Companion Diagnostics Market Overview
24.2. USA Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oncology Companion Diagnostics Market

25.1. Canada Oncology Companion Diagnostics Market Overview
25.2. Canada Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oncology Companion Diagnostics Market

26.1. South America Oncology Companion Diagnostics Market Overview
26.2. South America Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oncology Companion Diagnostics Market

27.1. Brazil Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oncology Companion Diagnostics Market

28.1. Middle East Oncology Companion Diagnostics Market Overview
28.2. Middle East Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oncology Companion Diagnostics Market

29.1. Africa Oncology Companion Diagnostics Market Overview
29.2. Africa Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oncology Companion Diagnostics Market Competitive Landscape And Company Profiles

30.1. Oncology Companion Diagnostics Market Competitive Landscape
30.2. Oncology Companion Diagnostics Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Bayer Diagnostic Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis

31. Oncology Companion Diagnostics Market Other Major And Innovative Companies

31.1. Laboratory Corporation of America Holdings (LabCorp)
31.2. Quest Diagnostics Incorporated
31.3. Eurofins Scientific SE
31.4. Agilent Technologies Inc.
31.5. Illumina Inc.
31.6. PerkinElmer Inc.
31.7. bioMerieux SA
31.8. Sysmex Corporation
31.9. Bio-Rad Laboratories Inc.
31.10. QIAGEN N.V.
31.11. Exact Sciences Corporation
31.12. BGI Genomics Co. Ltd.
31.13. Natera Inc.
31.14. Myriad Genetics Inc.
31.15. ARUP Laboratories

32. Global Oncology Companion Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oncology Companion Diagnostics Market

34. Recent Developments In The Oncology Companion Diagnostics Market

35. Oncology Companion Diagnostics Market High Potential Countries, Segments and Strategies

35.1 Oncology Companion Diagnostics Market In 2029 - Countries Offering Most New Opportunities
35.2 Oncology Companion Diagnostics Market In 2029 - Segments Offering Most New Opportunities
35.3 Oncology Companion Diagnostics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer